Name: Bridging the Translational Science Divide by The Bioverge Podcast
Duration: 39 min 43 s
Description: Pete Schultz, CEO of Scripps Research, sits down with Neil to discuss his efforts to create a self-sustaining nonprofit drug discovery and development institute and it’s work to advance small molecule regenerative therapies from the lab to the clinic.

Anthony DePasqua, CEO of EnClear Therapies, sits down with Neil to discuss the company’s technology in development to remove toxic proteins from cerebrospinal spinal fluid to treat patients with ALS and other neurodegenerative conditions.

Removing Toxins from Cerebrospinal Fluid to Treat Neurodegenerative Diseases

Pete Schultz, CEO of Scripps Research, sits down with Neil to discuss his efforts to create a self-sustaining nonprofit drug discovery and development institute and it’s work to advance small molecule regenerative therapies from the lab to the clinic.

Bridging the Translational Science Divide

Join Neil Littman on The Bioverge Podcast as he explores the intersection of bio x tech and features the entrepreneurs, investors, and industry leaders who are revolutionizing healthcare and bringing science fiction to life.

Bridging the Translational Science Divide

The Bioverge Podcast

Related tracks